Results 111 to 120 of about 26,068 (276)
Improving Postdischarge Outcomes in Acute Heart Failure [PDF]
, 2018 The global burden that acute heart failure (AHF) carries has remained unchanged over the past several decades (1). European registries (2–5) showed that 1-year outcome rates remain unacceptably high (Table 1) and confirm that hospitalization for AHF ...
Ambrosy, Andrew P. +8 more
core +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1227-1236, April 2025.Comparative performance of 7 risk prediction indices in patients hospitalized for heart failure. In this cohort of 1206 patients, the LENT index offered the greatest discrimination, calibration, and overall accuracy in predicting 30‐day composite all‐cause mortality or readmission following hospitalization for heart failure.
Tauben Averbuch +8 more
wiley +1 more source
Hyperkalemia and Renin-Angiotensin-Aldosterone System Inhibitors Dose Therapy in Heart Failure With Reduced Ejection Fraction. [PDF]
, 2019 Renin-angiotensin-aldosterone system inhibitors (RAASi) are known to improve outcomes in patients who have heart failure with reduced ejection fraction (HFrEF).
Agewall, S +3 more
core +2 more sources
ESC Heart Failure, Volume 12, Issue 2, Page 1237-1245, April 2025.Abstract Aims Immune checkpoint inhibitors (ICI) are the cornerstone of modern oncology; however, side effects such as ICI‐related myocarditis (irM) can be fatal. Recently, Bonaca proposed criteria for irM; however, it is unknown if they correlate well with cardiovascular (CV) ICI‐related adverse events.
Lorenzo Braghieri +12 more
wiley +1 more source
SPIRONOLACTONE FOR NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY: A RANDOMIZED CONTROLLED CROSSOVER STUDY. [PDF]
, 2015 PURPOSE: To evaluate the effect of spironolactone, a mineralocorticoid receptor antagonist, for nonresolving central serous chorioretinopathy. METHODS: This is a prospective, randomized, double-blinded, placebo-controlled crossover study. Sixteen eyes of
Batista, R. +11 more
core +4 more sources
ESC Heart Failure, Volume 12, Issue 2, Page 1246-1255, April 2025.Abstract Aims Myocardial inflammation and impaired mitochondrial oxidative capacity are hallmarks of heart failure (HF) pathophysiology. The extent of myocardial inflammation in patients suffering from ischaemic cardiomyopathy (ICM) or dilated cardiomyopathy (DCM) and its association with mitochondrial energy metabolism are unknown.
Julius Borger +15 more
wiley +1 more source
Adipocytes, aldosterone and obesity-related hypertension [PDF]
, 2016 Understanding the mechanisms linking obesity with hypertension is important in the current obesity epidemic as it may improve therapeutic interventions.
Friederich-Persson, Malou +3 more
core +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1479-1484, April 2025.Abstract Aims The VICTORIA trial demonstrated a significant reduction in the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death with vericiguat relative to placebo in high‐risk HF. This study aimed to contextualize treatment effects of vericiguat in populations with varying risk profiles simulated from the PARADIGM ...
Veraprapas Kittipibul +13 more
wiley +1 more source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular DiseaseBackground Randomized trials and clinical guidelines support early initiation of guideline‐directed medical therapy (GDMT) for heart failure (HF). The EMPACE (Treatment Patterns of Guideline‐Directed Medical Therapies in Heart Failure Patients in the ...
Stephen J. Greene +9 more
doaj +1 more source
Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study‐Heart Failure (ARTS‐HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease [PDF]
, 2015 Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/110733/1/ejhf218 ...
Albert +39 more
core +2 more sources